Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies-Reference-Cited by-同舟云学术

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Published:2022-09-21 Issue:3 Volume:35 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Heyckendorf Jan¹²³⁴,Georghiou Sophia B.⁵,Frahm Nicole⁶,Heinrich Norbert⁷,Kontsevaya Irina²³⁴,Reimann Maja²³⁴,Holtzman David⁵,Imperial Marjorie⁸,Cirillo Daniela M.⁹^ORCID,Gillespie Stephen H.¹⁰,Ruhwald Morten⁵^ORCID,

Affiliation:

1. Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany

2. Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany

3. German Center for Infection Research (DZIF), Braunschweig, Germany

4. International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany

5. FIND, the Global Alliance for Diagnostics, Geneva, Switzerland

6. Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA

7. Division of Infectious Diseases and Tropical Medicine, Medical Centre of the University of Munich (LMU), Munich, Germany

8. University of California San Francisco, San Francisco, California, USA, United States

9. Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

10. School of Medicine, University of St Andrews, St Andrews, Fife, Scotland

Abstract

Despite the advent of new diagnostics, drugs and regimens, tuberculosis (TB) remains a global public health threat. A significant challenge for TB control efforts has been the monitoring of TB therapy and determination of TB treatment success.

Funder

Innovative Medicines Initiative

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/cmr.00227-21

Reference165 articles.

1. WHO. 2020. Global tuberculosis report. World Health Organization Geneva Switzerland.

2. WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization Geneva Switzerland.

3. WHO. 2017. Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). World Health Organization Geneva Switzerland.

4. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

5. Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles;The Lancet Microbe;2024-09

2. Exploring mean platelet volume and neutrophil-to-albumin ratio as surrogate markers for monitoring tuberculosis treatment: a prospective longitudinal study;BMC Pulmonary Medicine;2024-08-23

3. Development and preliminary evaluation toward a new tuberculosis treatment monitoring tool: the PATHFAST TB LAM Ag assay;Journal of Clinical Microbiology;2024-08-14

4. Pharmacokinetic–pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid;Antimicrobial Agents and Chemotherapy;2024-08-07

5. A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB;Journal of Antimicrobial Chemotherapy;2024-08-01